Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apellis Pharmaceuticals, Inc. - Common Stock (NQ: APLS ) 33.32 +0.11 (+0.33%) Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 437,759 Open 33.21 Bid (Size) 32.31 (5) Ask (Size) 33.50 (1) Prev. Close 33.21 Today's Range 32.50 - 33.39 52wk Range 24.34 - 73.80 Shares Outstanding 116,457,008 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm December 23, 2024 From Bragar Eagel & Squire Via GlobeNewswire Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session December 17, 2024 Via Benzinga Performance YTD -45.62% -45.62% 1 Month +4.42% +4.42% 3 Month +8.92% +8.92% 6 Month -17.59% -17.59% 1 Year -44.56% -44.56% More News Read More This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday December 17, 2024 Via Benzinga Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings) December 17, 2024 Via Benzinga A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts November 21, 2024 Via Benzinga A Glimpse of Apellis Pharmaceuticals's Earnings Potential November 04, 2024 Via Benzinga The Latest Analyst Ratings For Apellis Pharmaceuticals November 04, 2024 Via Benzinga Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Present at Upcoming Investor Conferences November 27, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday November 19, 2024 Via Benzinga Navigating 18 Analyst Ratings For Apellis Pharmaceuticals October 16, 2024 Via Benzinga Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference November 12, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday November 06, 2024 Via Benzinga Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday November 05, 2024 Via The Motley Fool Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales November 05, 2024 Via Investor's Business Daily Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session November 05, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session November 05, 2024 Via Benzinga Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results November 05, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire 1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst October 29, 2024 Via The Motley Fool Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN October 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results October 22, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch October 16, 2024 Via Benzinga Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN October 16, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 04, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day September 25, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
